Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.

Published in: Journal of immunology research (2022)

The novel PIV was able to independently stratify newly diagnosed GBM patients into two groups with fundamentally different PFS and OS outcomes following RT and concurrent plus adjuvant TMZ.

Keyphrases

newly diagnosed
early stage
end stage renal disease
locally advanced
ejection fraction
oxidative stress
chronic kidney disease
radiation therapy
prognostic factors
squamous cell carcinoma
patient reported